Education
About Us
Working with TipRanks
Follow Us
Immucell Corp. (ICCC)
NASDAQ:ICCC
ICCC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.34 - $7.60
Previous CloseN/A
Volume9.49K
Average Volume (3M)13.07K
Market Cap
$60.10M
Enterprise Value$53.08M
Total Cash (Recent Filing)$4.60M
Total Debt (Recent Filing)$14.66M
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Nov 17, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding9,037,397
10 Day Avg. Volume7,543
30 Day Avg. Volume13,066
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$7.00Price Target Upside4.17% Upside
Rating ConsensusHold
Number of Analyst Covering1
Immucell News
ICCC FAQ
What was Immucell Corp.’s price range in the past 12 months?
Immucell Corp. lowest stock price was $3.34 and its highest was $7.60 in the past 12 months.
What is Immucell Corp.’s market cap?
Immucell Corp.’s market cap is $60.10M.
When is Immucell Corp.’s upcoming earnings report date?
Immucell Corp.’s upcoming earnings report date is Nov 17, 2025 which is in 94 days.
How were Immucell Corp.’s earnings last quarter?
Immucell Corp. released its earnings results on Aug 14, 2025. The company reported $0.056 earnings per share for the quarter, beating the consensus estimate of N/A by $0.056.
Is Immucell Corp. overvalued?
According to Wall Street analysts Immucell Corp.’s price is currently Undervalued.
Does Immucell Corp. pay dividends?
Immucell Corp. does not currently pay dividends.
What is Immucell Corp.’s EPS estimate?
Immucell Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immucell Corp. have?
Immucell Corp. has 9,037,397 shares outstanding.
What happened to Immucell Corp.’s price movement after its last earnings report?
Immucell Corp. reported an EPS of $0.056 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Immucell Corp.?
Currently, no hedge funds are holding shares in ICCC
Immucell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.00 (4.17% Upside)
$7.00 (4.17% Upside)
Insider Transactions
Bought Shares
Worth $6.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.67%
12-Months-Change
Fundamentals
Return on Equity
-1.01%
Trailing 12-Months
Asset Growth
5.97%
Trailing 12-Months
Company Description
Immucell Corp.
Immucell Corporation (ICCC) is a publicly traded biotechnology company focused on developing and commercializing innovative products for the veterinary health market. The company primarily operates in the animal health sector and specializes in creating products that enhance the health and productivity of livestock, particularly dairy and beef cattle. Immucell's core product offerings include its flagship product, First Defense, which is designed to prevent disease in newborn calves by providing them with essential immunoglobulins.
ICCC Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong sales growth, improved gross margins, and significant adjusted EBITDA performance, driven by increased production capacity and product line expansion. However, challenges remain with FDA licensing for Re-Tain and managing backlog, alongside potential sales variability due to seasonality.View all ICCC earnings summariesICCC Stock 12 Month Forecast
Average Price Target
$7.00
▲(4.17% Upside)
Technical Analysis
Ownership Overview
1.58% Insiders
3.59% Mutual Funds
1.45% Other Institutional Investors
89.66% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---